<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 365 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page364.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=365">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 365 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 365</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=365"><img src="../thumb/365.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>328 / 2020-04                                                             Immunological - 24.1
   method). Sirolimus lev. will decr.when cyclospor.is discont. On aveg.   rectovagin.fistula and maint.of fistula clos.in fistulis.Crohn’s dis., act.  ULN develop & investig., no studies in liv./ ren.dis., adeq.contracept.
   Rapamune dos.will be 4-fold.high to account for absence of phar-  ulcerat.colit. in adults&paeds. where respons.to convent.ther. inadeq.  in child bear.women x6 mnths.aft.last treatm.
   macokinet.interact.(2-fold incr) and augment immunosuppress.re-  (S4) POWD.FOR INFUS, 33/30.1/0531  See also MDR page 417.
   quirem.in cyclospor. absence. (2-fold incr). Incr.dos.to correspond.  707507-001: 100 mg, R5 569,07  REVLIMID, Key Oncologics
   to cyclosporin eliminat.rate. Retain pts.on new dly. maint. dos for at   Dosage: See product lit.for prep.& admin.techniq. Safety & effic.be-
   least 7-14 days bef.furth.dos. adjustm. with conc.monit. Consid.load.  yond recomm.durat.not est. Admin. by exper.physic.only. Observ.for   Lenalidomide
                                                              Indications: Transfus.-depend.anaem.due to low- or intermed.-1-
   dos.in addit. to new maint.dos.when a considerable incr.in sirolimus   1-2 hrs. post infus. Facilit.for treat.anaphylax.to be avail.
   trough conc.necess. Load.dos.=3x (maint. dos.- curr.maint.dos). Max.  Rheumat.arthrit: Re-admin.not recomm.aft.16 wk med.free period   risk myelodysplast.syndr.(MDS) assoc. with a delet.5q cytogenet.
                                                              abnorm.with/-out other cytogenet. bnormalit., in combinat.with
   sirolimus dos.on any day 40 mg. If estimat.dly.dos.exceeds 40 mg   due to delay.hypersens.react. Admin. in conjunct.with methotrex. In-
   due to addit.of load.dos.admin.load.dos.over 2 days. Monit.trough   fus.IV over2 hrs. Adults: Init.3 mg/kg to be follow.2 & 6 wks. aft. 1   st  dexamethasone for treatm. of multiple myeloma pts. who have
                                                              receiv.at least one prior ther.
   conc.3-4 days aft.load.dos.  infus.with addit. 3 mg/kg infus. Infus.to be rep. every 8 wks.there-  (S4) CAPS 47/32/0507, 0508, 0509, 0510
                       2
   Pts.≥ 13 yrs.weigh &lt; 40 kg: Load.dos: 3 mg/m . Adjust maint.dos.  aft. Clin.respon.usually achiev.within 12 wks.of treatm. If respon.in-
   bas.on body surf.area to 1 mg/m /day.  adeq./ lost aft.this period dose may be incr.step-wise by approx. 1.5   709425-002: 5 mg, 21 R57 438,73
                 2
                                                              711342-002: 10 mg, 21, R60 781,46
   Mild/mod.hepat.impairm: Reduc.maint.dos.by approx one third  mg/kg up to max.7.5 mg/kg every 8 wks. Alternat.admin 3 mg/kg
   Sev hepat.impairm: Reduc.maint.dos.by approx half  as oft.as every 4 wks. may be consid. If adeq.respon.achiev.contin.  712414-002: 15 mg, 21, R60 781,46
                                                              709424-002: 25 mg, 21, R60,781,46
   Contraindications: Pregn., lactat., de novo liv./ lung trans-  pt.on select.dos./dos.freq. Careful.reconsid.contin. ther. in pts.show.
                                             st
   plant., grapefruit juice, safety & effic.in paed. pts.und.13 yrs.not   no evid.of ther.benef.within 1  12 wks. of treatm./aft.dose adjustm.  Dosage: Take orally at same time dly. do not open/break.chew caps.
                                                              Myelodysplast.syndr: Recomm.start.dos: 10 mg once dly.on
   est., lact.intol.            Ankylos.spondylit: IV infus.of 5 mg/kg over 2 hrs. follow.by ad-
                                                 st
   Side effects: Lymphocele, periph.oed., abnorm. heal., oed., fev.,   dit.5 mg/kg infus.dos.at 2 & 6 wks.aft. 1  infus.then every 6-8 wks.  days 1-21 of repeat.28-day treatm .cycles. Adjust/interr.dos.accord.
                                                              to clinic.& lab.results (refer to prod.lit.for dos.adjustm. guidelines) in
   fung./vir.& bact.infect., Herpes simplex, sepsis, lymphoed., tachy-  thereaft. Data support. re-admin.other than every 6-8 wks.not avail.  pts.exper.thrombocytopen.
   card., ven. thromboembol., pericard.effus.incl.haemodynamic. sig-  Psoriat.arthrit: IV infus.of 5 mg/kg over 2 hrs. follow. by addit.5 mg/  Prev.treat.multiple myeloma: Recomm.start. dos: 25 mg/day
                                             st
   nific.effus., abdom.pain, diarrh., stomatit., ascites, pancreatit., bld.  kg infus.dos.at 2 & 6 wks. aft. 1  infus.then every 8 wks.thereaft. Data   on days 1-21 of repeat.28-day cycles. Recomm.dexamethasone dos:
   dyscras., hypercholesterolaem., hypertriglyceridaem., leucopaen.,   support. re-admin.other than every 8 wks.not avail.  40 mg/day on days 1-4, 9-12, & 17-20 of each 28-day cycle for 1st 4
   neutropaen., thrombot. thrombocytopen. purpura/hemolyt.urem.syn-  Psorias: IV infus.of 5 mg/kg over 2 hrs.follow.by addit.5 mg/kg infus.  cycles of ther. & then 40 mg/day on days 1-4 every 28 days. Contin.
                                         st
   dr., lymphoma/post-transpl.lymphoproliferat.disord., pancytopaen.,   dos.at 2 & 6 wks.aft.1  infus. then every 8 wks.thereaft. Data support.  treatm. until dis.progress./ unaccept.toxic. Adjust./interr.dos.accord.
   hypersens.reacts.incl.anaphylax., hypokalaem., incr.LDH, abnorm.  re-admin. other than every 8 wks.not avail.  to clinic. & lab.results (refer to prod.lit.for dos.adjustm. guidelines)
   liv funct.test., incr.ALT & AST, fluid accum., arthralg., bone necros.,   Mod to sev.Chron’s dis: Re-admin.not recomm. aft. 16 wk.med.  to manage grade 3 or 4 netropen.or thrombocytopen.or other relat.
   epistax., pneumon., pneumonit., pulm. haemorrh., alveol.proteinos.,   free period due to delay. hypersens. react. Adults: 5 mg/kg as sngl.  grade 3 or 4 toxic.
   pleur.effus., acne, rash, squam.& bas.cell Ca, melanoma, exfoliat.   IV infus. over 2 hr.period as induct.regimen at 0, 2 & 6 wks. follow.by   Miss.dos: &lt; 12 hrs. since miss.dos: Take dose, &gt; 12 hrs. since
   dermatit., UTI, pyelonephrit., proteinur., foc. segment.glomeruloscle-  maint.5 mg/kg regim.every 8 wks. thereaft. Consid.adjust.dos.upto   miss.dos: Do not take dos, but take next dos.at norm.time on follow.
   ros., nephrot.syndr., joint disord., acidos., hypertens., CsA toxic., incr.   10 mg/kg for those with incomplete respons.dur.maint.treatm. Alter-  day. Do not take 2 dos.at same time.
   creatin., abnorm.kidn.funct., tox.nephropathy, hyperuricaem., gout,   nat.admin.init.5 mg/kg IV infus.over 2 hrs. follow. by rep.5 mg/kg infus.  Contraindications: Pregn. & lactat., women of childbear.potent.ex-
   gum hyperplas., skin Ca, incr.risk of ren.funct.deteriorat./ser.lipid   when S&S of dis. recur. but data limit.on dos.interv.beyond 16 wks.  cept when all condits.for pregn. prevent.met, prior history of Grade 4
   abnormalit.& UTI when combin.with calcineurin inhibit.& corticos-  Paed: Not stud.in childr.less than 6 yrs.of age. IV infus.of 5 mg/kg   rash assoc. with thalidomide, paeds.&lt;18 yrs., lact.intol.
                                                       st
   ter., in delay.graft funct.recov.of ren. funct. delay., interstit.lung dis.,   follow.by addit.5 mg/kg infus.dos. at 2 & 6 wks. aft.1  infus.then   Side effects: Pyrex, oed.(incl. periph.), influenza like illness syndr.,
   hepatotoxic. incl.fatal hepat.necros., abnorm.wound heal., abdom.   every 8 wks. thereaft. Consid.adjust.dos.upto 10 mg/kg for those   fatig., asthen., GI disords., musculoskelet. & connect.tiss. pain/dis-
   pain, asthen., headache, pain, hypertens, GI disturbs., hyperlipaem.,   with incomplete respons. Admin.with concom. immunomodulat.  comf., bone/back pain, musc.spasms, arthralg., myalg., musc.weakn.,
   hypophosphataem., trem., dyspn., pharyngit., abdom.enlargem., ac-  Fistulis.Chron’s dis: Re-admin.not recomm.aft. 16 wk.med.free   periph.neuropathy., dizzin., trem., dysgues., headache, lethargy, par-
   cid. injury., back/ chest pain, chills, fac.oed., peritonit., haemorrh.,   period due to delay.hypersens. react. Init.5 mg/kg as IV infus.over 2   aesthes., syncope, CVA, dyspn., epistax., resp.distress, bronchit.,
                                                      st
   hypervolaem., hypotens., oral monilias., Cushing’s syndr., diab.mellit.,   hrs.,follow.by addit.5 mg/kg dos.at wks 2 & 6 aft.1  infus. If no re-  pneumon., bact./vir./fung.infects., URTI, rash, prurit., dry skin, hy-
   ecchymos., leukocytos., acidos., incr.CPK, dehydrat., hypercalcaem.,   spons. aft.these 3 dos.do not admin.addit.treatm. Cont.treatm.strateg.  perhidros., neutropen., thrombocytopen., anaem., leukopen., febrile
   hyperglycaem., hyperkalaem., hypocalcaem./-magnesaem., weight   are addit.5 mg/kg infus.every 8 wks.or re-admin.if S&S recur.follow.  neutropen., decr.appet., hypokalaem., hypocalcaem., dehydrat., hy-
   gain, tetany, CNS effs., cough, rhinit., hirsut., prurit., skin disord.,   by 5 mg/kg infus.every 8 wks.  pomagnesaem., Fe overload, hypophosphataem., hyperglycaem.,
   sweat., abnorm.vis., albuminur., bladd. pain, dysuria, haematur.,   Adult/Paed.Ulcerat.colit: IV infus.of 5 mg/kg over 2 hrs. follow.by   blurr. vis., cataracts, ren.fail., VTE, hyper-/hypotens., haematoma,
                                                  st
   hydronephros., kidn. tubul. necros., oliguria, scrot.oed., urin.freq./-  addit.5 mg/kg infus.dos.at 2 & 6 wks. aft.1  infus.then every 8 wks.  depress., alt.mood, B-cell lymphom., hypersens./allerg.reacts., ab-
   incontin./-retent., azoosperm.revers.upon discontin.  thereaft. Data support. re-admin.other than every 8 wks.not avail.  norm.LFT, decr. weight, tumour lysis syndr., tumour flare react. trans.
   Special precautions: Oral admin.only,treatm.by special. physic.  In careful.select.adult pts. who have tolerat.at least 3 init.2-hr Revellex   abnorm.liv.lab.tests.
   only, effic.& safety in combinat. with other immunosuppress.agents   infus. & are receiv. maint. ther. consid.admin.subseq.infus.over a pe-  Special precautions and warnings: Struct. relat. to thalidomide,
   not determ., incr.risk of imp.wound heal.in pts.with BMI &gt;30 kg/  riod of not less than 1 hr. Shorten.infus.at dos. &gt; 6 mg/kg not studied.  poss.sev.life-threaten.birth defects, if tak.dur.pregn.teratogen.eff.ex-
   m , immunosuppress.incr.risk of develop. lymphomas/ other ma-  Contraindications: TB & other sev.infects.eg. sepsis/abscess/op-  pect., only precrib./pharmacist register.with key assist risk managem.
    2
   lign.partic.of skin, limit. sunlight & UV expos., consid.risk: benef.in   portunist.infects., mod.to sev.HF (NYHA class III/IV), concom.anakinra   program.are allow.to prescrib./ dispense, pts.must be advis.of/agree
   est. hyperlipidaem.bef.init.ther., to consid.post-op meas. to minim.  not recomm., safety in pregn.& lactat. not est., safety & effectiven.   to/comply with requirem. of key assist risk managem.progr., women
   poss.lymphocele complicat., monit. for hyperlipidaem., monit.for   not est.in juven.rheumat.arthrit.  of childbear.potent.must use 2 reliable methods of contracept.for
   rhabdomyolys. with concom. cyclospor.& HMG-CoA reduct.inhibit./   Side-effects: Human antichimeric antibody (HACA) posit.pts.more   4 wks.bef.ther./dur. ther. incl.dose interrupt.& and until 4 wks. aft.
   fibrates, monit. ren.funct.as concom.cyclospor. incr. ren.funct.decl.,   likely to exper.infus.reacts., infus.relat.ac.or delay.hypersens.reacts.  ther., ensure contracept.in men dur.& for 4 wk. aft. treatm., women
   only consid.continuat.of combinat. ther.with CsA beyond 4 mnths.  incl. anaphylax., developm.of anti-dsDNA antibod., lupus-like syndr.,   of childbear.potent.to undergo pregn. test.7 days bef.start.treatm./
   follow. transplant. in pts.at low to mod.immunolog.risk if benef.&gt; risk,   vir./bact.& other opportunist. infects., bld.dyscras., ser.sickn.& lupus-  every 4 wks. dur. /4 wks.aft.discontinuat. except in case of confirm.
   incr.urin.prot.excret.assoc.with convers. from calcineurin inhibit in   like reacts., resp.tract allerg.reacts., psych.disords., headache, vertigo,   tubal sterilisat., pts.not to donate bld./ sperm dur./4 wks.aft.discon-
   maint.ren. transplant pts., safety of convers.from calcineurin inhibit   dizzin., exacerbat.of demyelin.dis.suggest. MS, meningit., conjunc-  tin., discont.immed.if pregn.occur dur.treatm., caut.when erythropoiet.
   in maint.ren.transplant pts.not est.safety & effic.of de novo Rapam-  tivit., endophthalmit., keratoconjunctivit., periorbit.oed., syncope,   agents/other agents incr.risk of thrombos.used in multiple myeloma
   unce use without a calcineurin inhibit.not est.in ren.transplant.pts.,   bradycard., palpitat., cyanos., arrhythm., worsen. HF, tachycard., flush.,   pts.receiv.Revlimid with dexamethasone, comb.oral contracept.pills
   Pneumocystis carinii pneumon.antimicrob. prophylax. for 1 yr.post   ecchymos., haematoma., hyper-/hypotens., petech., thrombophlebit.,   not recomm.due to incr.risk of ven.thromboembol., interr.ther/consid.
   transplant., CMV prophylax. x3 mnths.recomm.when risk incr., effect.   vasosp., periph.ischaem., circulat.fail., system.& cutan.vasculit., pso-  discont.for grade 2-3 skin rash., discont.ther.and do not resume for
   contracept.dur.ther.& x12 wks.aft.stop., CsA withdr. not recomm.in   rias.(incl.new onset& pustul, pericard.& pleur.effus., U&LRTI, dyspn.,   angioed./Grade 4 rash/exfoliat. or bull.rash/suspect.Stev.-Johns.
   high risk ren.transplant pts.as not adeq.stud., strong CYP3A4 & P-gp   sinusit., epistax., bronchosp., pleurisy, GI disords.incl. intest. perforat./  syndr.or toxic epiderm. necrolys., pts.at risk for tumour lysis syndr.&
   induc. /inhibit. not recomm.theref.consid.alternat.ther.if indicat., vac-  stenos.& haemorrh., abnorm. hepat.funct., cholecystit., hepatit., skin   tumour flare react., haematolog. toxic.risk, MDS: perform FBC (incl.
   cinat.less effect., avoid live vaccines, maint. dos.adjustm.in pts.exper.  reacts. incl.fung.dermatit./onychomycos./abnorm. skin pigmentat.&   WBC count with differ., platelets, haemoglob. & haematocr.) at
   ac.hepat.impairm. post-transplantat., monit.whole bld.trough lev.in   alopec., myalgia, arthralg., back pain, UTI, pyelonephrit., vaginit.,   baseline/wkly for 1st 8 wks.& mnthly thereaft., in prev.treat.multi-
   hepat. impairm./pts.rec.conc.contr.Rapamune/ paeds./ dur.concom.  fatig., chest pain, inj. loc.reacts., imp.heal., granulomat.les., elev.   ple myeloma monit.FBC every 2 wks.for 1st 12 wks & then mnthly.
   admin.of CYP3A4 & P-gp induc. or inhibit./if CsA dos.markedly re-  hepat. transaminas., auto-antibod., complem.fact. abnorm., periph.  thereaft., careful.eval.pts bef.& dur. treatm. for occurr.of second prim.
   duc.or CsA discont., risk for opportunist.infect.incl.activat.of lat. vir.  myelinat.disords., neuropath., numbness., tingl., seiz., transvers.  malign.& instit. treatm.as appropr., monit.warfarin conc.with concom.
   infect., consid.BK vir.assoc.nephropath.as different.diagnos.in im-  myelit., pancytopen., haemolyt.anaem., idiopath. thrombocyt. purp.,   dexamethasone, elderly, ren.impairm.
   munosuppress.pts.with deteriorat. ren.funct.  thrombot.thrombocyt.purp., Stev.-Johns.Syndr., tox.epiderm.necrolys.,   Drug interactions: Digoxin C max and AUC 0-∞ poss.incr., poss.incr.VTE
   Drug interactions: Reduc.cyclospor.clear.aft.6 mnths. multip.dos.  eryth. multif., agranulocytos., hepatocellul.damage, hepatit.B reacti-  risk with concom.oral contracept/HRT.
   admin.necessitat.low. cyclosporin dos., cyclospor.inhibit.metabol.,   vat., jaund., autoimmune hepatit., liv.fail., pancreatit., interstit.pneu-
   diltiazem aff.sirolimus bioavail., ketoconaz.affect. absorpt., rifampic.  monit., rare type hepatosplen.T-cell lymphoma in adolesc.& young   SANDIMMUN, Novartis [P/S]
   decr.bld.conc., CYP3A4 & P-gp inhibit. incr.bld.lev., CYP3A4 & P-gp   adult Crohn’s dis.pts., trans.vis.loss, myocard. ischaem./MI within 2   Ciclosporin.
   induc.decr. bld. lev., other meds.that may incr.bld.lev.incl. nicardi-  hrs of infus., interstit.lung dis.  Indications: Prophylax.of graft reject.aft.kidn./ liv./ pancreas/heart,
   pine /verapamil/diltiazem/clotrimazole/ fluconazole/ itraconazole/  Warnings and special precautions: Eval.TB incl.latent TB & other   combin.heart, lung & bone marr. transplant, prevent.of graft-vs-host
   ketoconazole/ clarithromyc. / erythromyc./telithromycin/ trolean-  opportunist.infect.risk bef. init.ther., treat.clinic.manifest.infects.prior   dis.aft. bone marr.transplant., treatm.of transpl.reject.in pts. prev.re-
   domyc./ cisapride/metoclopramide/ bromocriptine/ cimetid./cyclo-  to ther. & monit.closely, prophylact.anti-TB ther.if latent TB diagn.  ceiv.other immunosuppress.agents, est.graft vs host dis.treatm., sev.
   sporin/danazol/HIV-protease inhibit., grapefruit juice, other meds.  prior to init.ther.& consid.benefit/risk bal., pts.to rep.sympts.sug-  psorias./sev.act. rheum.arthrit./atop.dermatit.where convent.ther.is
   that may decr.bld. lev.incl.carbamazepine/phenobarb/ phenytoin/   gest.of TB dur./aft. treatm., norm.immune respons.poss.aff., HF of   ineffect./inappropriate/risks of treatm.justif.
   rifabutin/ rifampicin/rifapentine & St John’s Wort., incr.risk of cal-  NYHA class I/II, antibody format.reduc.with concom. methotrex.&   (S4) INJ, [P/S] R/34/267. 50 mg/ml.
   cineurin inhibit.induc. HUS/TTP & TMA, angioneurot.oed.type re-  other immunomodulat.in rheumat.& psoriat.arthrit.& Chron’s dis.  762296-003: 10x1 ml, R725,74
   acts. with ACE inhibit.      pts., new onset HF without pre-exist. CV dis., poss.delay. hypersens.  (S4) NEORAL DRINK SOL, [P/S] 29/34/0059. 100 mg/ml.
   See also MDR page 638.       reacts.in pts.re-challeng.follow.period without treatm., concom im-  815896-018: 50 ml, R4 688,83
                                munosuppress.agents appear to reduc.infus.relat.reacts.freq., new/   (S4) NEORAL CAPS, [P/S] 29/34/0056, 0058.
   REVELLEX, Janssen [P/S] &    recurr. malign.report., lymphoma incid.high.than expect.in gen.pop-  815926-006: 25 mg, 50, R1 144,12
   Infliximab.                  ulat., host defence against infect.comprom., sympts.of infect.poss.  815918-003: 100 mg, 50, R4 505,21
   Indications: Act.rheumat.arthrit.despite methotrex. treatm., act.  masked, chron. infect./recurr.infect.hist., excl.source of infect. specif.  Dosage: Refer to manufact.product.lit.for further details.
   ankylos.spondylit., psoriat. arthrit. with/without methotrex.where   absecess.in fistulis.Chron’s dis.with ac. suppurat.fistul., safety exper.  Contraindications: Cremophor EL hypersens.for sol. for infus., in
   respons.to NSAID/dis.modify.drugs inadeq., sev.plaque psorias.  of surg.proced. limit., concom.live vacc.not recomm., discont.if sev.  non-transplant indicat.abnorm. ren. funct./uncontr.hypertens./uncontr.
   where system.ther.indicat., mod.psorias. where photother.inadeq./  hypersens.reacts.develops, discont.if sympts. suggest.of lupus-like   infects./any malign., concom.K-cont.medicat.& K-spar.diurets., safety
   inappropr., mod.to sev. act.adult/paed.Crohn’s dis.when respons.  syndr.develop, pre-exist./ recent onset CNS demyelinat.disords.,   in pregn.not est., lactat., avoid attenuat.live vaccine, childr.und.16 yrs.
   to convent.ther.inadeq., reduct.in the numb.of drain. enterocutan.&   malign.hist. / pts.develop.malign., discont.if jaund./ALT lev.&gt;5 times   for non-transpl.condits. as adeq.exper.not avail.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page364.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page360.html">360</a>&nbsp;&nbsp;&nbsp;<a href="page361.html">361</a>&nbsp;&nbsp;&nbsp;<a href="page362.html">362</a>&nbsp;&nbsp;&nbsp;<a href="page363.html">363</a>&nbsp;&nbsp;&nbsp;<a href="page364.html">364</a>&nbsp;&nbsp;&nbsp;<a href="page365.html">365</a>&nbsp;&nbsp;&nbsp;<a href="page366.html">366</a>&nbsp;&nbsp;&nbsp;<a href="page367.html">367</a>&nbsp;&nbsp;&nbsp;<a href="page368.html">368</a>&nbsp;&nbsp;&nbsp;<a href="page369.html">369</a>&nbsp;&nbsp;&nbsp;<a href="page370.html">370</a>
             </td>
             <td width="35%"><a href="page366.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page366.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
